TLDR
- Soleno Therapeutics (SLNO) surged over 30% in premarket trading Monday after reports of a buyout deal
- Neurocrine Biosciences (NBIX) is in advanced talks to acquire Soleno for $2.5B or more
- The deal could value SLNO in the low-to-mid $50s per share
- A deal could be finalised as soon as Monday, April 6, per the Financial Times
- Neurocrine fell 0.4% in premarket on the news
Soleno Therapeutics has had a rough 2026 — down around 14% year to date — but that changed fast on Monday morning.
Soleno Therapeutics, Inc., SLNO
The Financial Times reported that Neurocrine Biosciences is in advanced talks to buy the rare disease biotech in a deal worth more than $2.5 billion. The report sent SLNO surging over 30% in premarket trading.
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment https://t.co/t7RIhvgwIb
— Financial Times (@FT) April 6, 2026
The deal would value Soleno in the low-to-mid $50s per share. Discussions are moving quickly, and the FT said a deal could be agreed as soon as Monday.
Soleno’s core asset is Vykat XR, a drug it launched last year to treat hyperphagia — a condition linked to Prader-Willi syndrome. Hyperphagia causes extreme, persistent hunger that can lead to serious complications including stomach rupture, choking, obesity, and cardiovascular disease.
Prader-Willi syndrome is a rare genetic disorder, occurring in roughly one in every 15,000 live births. Vykat XR is the first commercialised drug approved to treat the hunger-related symptoms of the condition.
Analysts have forecast peak annual sales of up to $2.3 billion for Vykat XR — a number that clearly caught Neurocrine’s attention.
Neurocrine Moves Into Rare Disease
Neurocrine currently carries a market cap of around $13.21 billion. Its portfolio includes Ingrezza, which treats involuntary movements tied to Huntington’s disease, along with several other approved drugs and a pipeline of candidates.
Adding Vykat XR would give Neurocrine a foothold in the rare disease and orphan drug space, where pricing power tends to be strong and competition limited.
Neurocrine’s stock dipped 0.4% in premarket trading Monday. That’s a fairly typical reaction when a buyer enters an acquisition — investors price in the premium being paid.
SLNO’s Run-Up in Context
Even with Monday’s spike, SLNO was down around 14% in 2026 heading into this week. The stock had struggled despite analyst optimism around Vykat XR’s commercial potential.
On TipRanks, SLNO holds a Strong Buy consensus from 11 analysts. The average price target sits at $101.09, with the highest at $125.
At the reported deal price of low-to-mid $50s per share, the acquisition would come in well below those analyst targets — though it would represent a substantial premium to where SLNO had been trading recently.
The Financial Times report cited sources familiar with the matter, noting discussions are progressing well and moving rapidly toward a potential agreement.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
